(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 April 2019 (25.04.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/078920 A1

(51) International Patent Classification:
A61K 31/00 (2006.01) *A61K 31/4365* (2006.01)
A61K 31/4178 (2006.01) *A61K 31/426* (2006.01)
A61K 31/4152 (2006.01) *A61K 31/427* (2006.01)
A61K 31/4155 (2006.01) *A61K 31/496* (2006.01)
A61K 31/4166 (2006.01) *A61P 35/00* (2006.01)
A61K 31/192 (2006.01)

(21) International Application Number:
PCT/US2018/030100

(22) International Filing Date:
30 April 2018 (30.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/572,791	16 October 2017 (16.10.2017)	US
62/617,745	16 January 2018 (16.01.2018)	US
62/630,594	14 February 2018 (14.02.2018)	US

(71) Applicant: **ARAGON PHARMACEUTICALS, INC.** [US/US]; 12780 El Camino Real, Suite 301, San Diego, California 92130 (US).

(72) Inventor: **MOLINA, Arturo**; 12171 Hilltop Drive, Los Altos, California 94024 (US).


(74) Agent: **SHIRTZ, Joseph F.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

FIG. 3



(57) Abstract: Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.

[Continued on next page]

WO 2019/078920 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*